Skip to content

Factors Influencing Adherence to Adjuvant Endocrine Therapy

Factors Influencing Adherence to Adjuvant Endocrine Therapy in Women With Early Breast Cancer in Croatia

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06192446
Enrollment
1000
Registered
2024-01-05
Start date
2021-09-20
Completion date
2024-09-20
Last updated
2024-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adherence, Treatment

Brief summary

Breast cancer is the most common type of cancer and the leading cause of cancer death in women. Adjuvant endocrine therapy (AET) reduces the risk of disease recurrence and mortality in women with hormone-dependent breast cancer. This cross-sectional study aims to investigate adherence to AET and identify factors associated with adherence in the Republic of Croatia. The level of adherence, beliefs about medicines, and quality of life with AET will be investigated with validated instruments in the form of an anonymous survey. Given the available data on suboptimal adherence to AET in Europe and globally, it is clear that there is a need for investigating adherence in Croatia which hasn't been done so far. Each country, population, and health system has its own characteristics, and understanding the experience of using AET and identifying associated psychosocial factors could help in developing specific interventions supporting women and improving AET adherence.

Interventions

DRUGSurvey using a questionnaire.

An observational study conducted in a cross-sectional manner using a questionnaire.

Sponsors

University of Zagreb
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum

Inclusion criteria

* women older than 18 years of age * clinical diagnosis of hormone receptor positive early breast cancer stages 0-III according to the American Joint Committee on Cancer (AJCC) classification * prescribed with adjuvant endocrine therapy for more than 3 months

Exclusion criteria

* advanced metastatic breast cancer, stage IV according to the American Joint Committee on Cancer (AJCC) classification * other life-threatening illnesses * mental disorders * behavioral disorders caused by the use of psychoactive substances * behavioral syndromes related to physiological disorders and physical factors * cognitive impairment * organic and symptomatic mental disorder * schizophrenia * disorders similar to schizophrenia * delusional disorders * personality disorders * behavior disorders * mental retardation * psychological development disorders * unspecified mental disorders * Incapable of autonomously reaching decisions

Design outcomes

Primary

MeasureTime frameDescription
Patient adherence to adjuvant endocrine therapy assessment: Measurement of the level of adherence to adjuvant endocrine therapyDay 1.The overall aim of the study is to determine the proportion of women adherent to oral adjuvant endocrine therapy (AEL) after the diagnosis of breast cancer in Croatia, as well as to investigate the association between AEL adherence, medication beliefs, quality of life, sociodemographic, and clinical factors.

Secondary

MeasureTime frameDescription
Beliefs About MedicinesDay 1.Investigate medication beliefs using the Medication Beliefs Questionnaire (BMQ).
Prevalence of Treatment-Emergent Adverse Events as assessed by FACT-ESDay 1.Examine the quality of life using the Quality of Life Questionnaire with endocrine symptoms (FACT-ES).

Countries

Croatia

Contacts

Primary ContactIva Mucalo
imucalo@pharma.hr+3851 6461 802
Backup ContactFaculty of Pharmacy and Biochemistry
cpf@pharma.hr+3851 6394 411

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026